Should you be as excited as the analysts who think these stocks are two-baggers in the making?
News & Analysis: TransEnterix
An analyst upgrade fueled optimism for the beaten-down stock.
Sales of the company's Senhance robotic surgery system took a discouraging dip in the first quarter.
TRXC earnings call for the period ending March 31, 2019.
TRXC earnings call for the period ending December 31, 2018.
Shares slump after the company reports a fourth quarter that missed the mark.
TransEnterix was one of the few biotech stocks to escape the market's wrath last year. Here's why.
A market downturn that hit biotech stocks across the board and a dilutive share offering pressured shares of the robotic surgery upstart.
Shares jumped after the company provided investors with a slew of positive updates. Here are the key takeaways for investors.
An early progress report couldn't help the robotic-surgery stock hang on to previous gains.